TILD + matching placebo injections
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Active Psoriatic Arthritis
Conditions
Active Psoriatic Arthritis
Trial Timeline
Jul 1, 2020 → Dec 22, 2025
NCT ID
NCT04314544About TILD + matching placebo injections
TILD + matching placebo injections is a phase 3 stage product being developed by Sun Pharmaceutical for Active Psoriatic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT04314544. Target conditions include Active Psoriatic Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Active Psoriatic Arthritis were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04314544 | Phase 3 | Completed |
| NCT04314531 | Phase 3 | Active |
Competing Products
20 competing products in Active Psoriatic Arthritis